Bioventix (LSE:BVXP), the specialist antibody developer behind components used in hospital blood tests around the world, is approaching the reporting season for its financial year ended 30 June 2026. There have been no fresh regulatory announcements from the company over the past three months, with the most recent filing being a modest share purchase by its chief financial officer in June. That leaves its interim results, published in March 2026, as the latest detailed guide to how the business is performing.
What the company does
Bioventix develops and supplies high-affinity sheep monoclonal antibodies for use in clinical diagnostics. Most of these antibodies are built into tests run on automated blood-testing machines in hospitals and laboratories, supplied by major in-vitro diagnostics companies. The company earns revenue in two ways: from physical sales of antibodies, which have historically made up about a quarter to a third of revenue, and from downstream royalties, which account for the majority. It is a small business, reporting 14 staff in its 2025 annual report.
Latest developments
In its interim results for the six months to 31 December 2025, published on 30 March 2026, Bioventix said trading remained in line with expectations for the year ending 30 June 2026, and the chairman and chief executive said they remained confident in the outlook. The most notable growth came from its tau antibodies, used in Alzheimer's disease research. Royalties from this area rose five-fold to about £150,000, although the company stressed they came solely from research-use assays, as no routine clinical tests using them have yet been approved. It noted that three of the phospho-Tau217 research assays developed by leading diagnostics companies, including Roche and Siemens, use at least one Bioventix antibody.
Troponin sales, used in heart attack diagnosis, were described as steady, while vitamin D and other core antibodies were broadly flat, with challenging conditions in China weighing on some revenue. On 24 June 2026 chief financial officer Bruce Hiscock bought 534 shares at 1,799p each.
Financial and dividend picture
For the half year, revenue fell to £6.16 million from £6.73 million, or £6.4 million at constant currency, while profit before tax eased to £4.85 million from £5.05 million. Cash rose to £5.3 million. The company declared an unchanged interim dividend of 70p per share, paid in April 2026. For the year to 30 June 2025, Bioventix reported revenue of £13.1 million, profit before tax of £10.1 million and total dividends of 150p per share. That compared with total dividends of 155p for the previous financial year.
Sector and index context
Bioventix is one of the more profitable smaller healthcare names in the FTSE AIM All Share Index, with margins reflecting its royalty-heavy model. Its fortunes are tied to the volume of tests run by its diagnostics partners and to the pace at which new assays, such as blood tests for Alzheimer's disease, move from research into clinical use.
Key risks
Bioventix relies on a small number of large customers, and its established products, such as vitamin D, are described by the company as mature. Currency movements affect reported revenue, and weakness in China has already had an impact. The timing of regulatory approvals for clinical tau tests is outside its control, and royalty income from troponin has yet to benefit from a revised label claim.
What to watch next
Investors will look to the full-year results, which last year were published in late October, for updated figures, the second interim dividend and any commentary on tau royalties. A research update on tau tangle pathology with the University of Gothenburg was also flagged as expected later in the year.






Please wait processing your request...